AIM: To explore curative effect of different drugs in treatment of senile wet macular degeneration.

METHODS: We selected 98 patients 98 eyes with senile wet macular degeneration from July 2014 to January 2016 in our hospital as the research subjects. They were divided into control group and research group as the administration sequence, 49 patients in each group. Research group was treated with ranibizumab. The control group was treated with Conbercept. Both once per month and for 3mo.

RESULTS: Uncorrected visual acuity, central macular retinal thickness and area of choroidal neovascularization(CNV)leakage before treatment of the two groups were not statistically different(P>0.05). At 1, 3 and 6mo after treatment, the uncorrected visual acuity was improved significantly, the central macular retinal thickness decreased significantly, and the area of CNV leakage decreased significantly(P<0.05). The differences on uncorrected visual acuity at 1mo after treatment, central macular retinal thickness and area of CNV were statistically significant(P<0.05), while those indexes at 3 and 6mo after treatment was not significant(P>0.05). In the follow up period, there was no severe complications in the two groups, such as persistent high intraocular pressure, retinal detachment or tear, endophthalmitis, or other systemic complications. There were subconjunctival hemorrhage in 10 eyes in research group, 8 eyes in control group, all of which recovered within 15d after treatment. Transient elevated intraocular pressure occurred in 7 eyes in research group, in 9 eyes in control group. The complication rates of the two groups were not significant(P>0.05).

CONCLUSION: In the clinical treatment of senile patients with wet macular degeneration, treatment effect of Conbercept is not obvious at the early stage, but the effect is equivalent later and more economical.